Liver health and drug safety: new insights on fexinidazole
NCT ID NCT05607173
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 34 times
Summary
This study tested how a single 1200 mg dose of fexinidazole is handled by the body in people with mild or moderate liver impairment compared to those with normal liver function. 21 adults took part to measure drug levels and safety. The goal was to understand if liver problems change drug exposure, which helps guide safe use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC FUNCTION ABNORMAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number: 100-0001
Sofia, 1612, Bulgaria
-
Investigational site 250-0001
Rennes, France
Conditions
Explore the condition pages connected to this study.